ArticleScientific reports2025
PTPRK promotes resiniferatoxin-induced postherpetic neuralgia via activating DUSP1/p38 MAPK signaling pathway in dorsal root ganglia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- TRPV1‑mediated central sensitisation: Core mechanisms of migraine chronification and novel targeted therapeutic strategies (Review).International journal of molecular medicine · 2026Review
- Avian coronaviruses induce inflammatory responses by activating p38/MAPK signaling and NLRP3/caspase-1 inflammasomes through sphingosine-1-phosphate receptor 1.Veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Postherpetic neuralgia (PHN) is a chronic pain condition that develops in the area of a previous herpes zoster (shingles) infection. Protein tyrosine phosphatase receptor type K (PTPRK) encodes a receptor-type protein tyrosine phosphatase involved in regulating cell signaling, growth, and neural development. p38 MAPK signaling pathway regulates cellular responses to stress, inflammation, and cytokines, influencing processes like cell differentiation, apoptosis, and immune response. This study aimed to discover the role of PTPRK in PHN and the underlying mechanism. Bioinformatics analysis was used to screen for differentially expressed genes and enrichment pathways of these genes in PHN and control groups. Resiniferatoxin (RTX) was used to induce rat PHN model. Mechanical allodynia and thermal hypoalgesia were assessed by measuring the paw withdrawal threshold and latency. The levels of inflammatory cytokines were detected by ELISA and RT-qPCR. Western blot was performed to analyze the protein levels of DUSP1/p38 MAPK signaling pathway. Results showed that PTPRK expression was increased in RTX-induced rat PHN model. Besides, PTPRK promoted mechanical allodynia, thermal hypoalgesia, and inflammation in RTX-induced rat PHN model via activating DUSP1/p38 MAPK signaling pathway in rat dorsal root ganglia (DRG) tissues. In addition, PTPRK overexpression promoted inflammation by activating DUSP1/p38 MAPK signaling pathway in rat DRG cells. In conclusion, PTPRK promoted RTX-induced PHN via activating DUSP1/p38 MAPK signaling pathway in DRG, which might provide a reference for the treatment of PHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.